KR101393405B1 - Cosmetic composition having anti-inflammation and skin regeneration effect - Google Patents

Abstract

The present invention relates to a cosmetic composition having anti-inflammatory and skin regenerating effects, and more particularly, to a cosmetic composition containing a Boswellia serrata resin extract as an active ingredient and a stearyl glycide The present invention relates to a cosmetic composition which provides excellent anti-inflammation and skin regenerating efficacy by using at least one of stearyl glycyrrhetinate and madecassoside.

Description

[0001] Cosmetic composition having anti-inflammation and skin regeneration effect [0002]

The present invention relates to a cosmetic composition containing a Boswellia serrata resin extract as an active ingredient and an antioxidant composition comprising stearyl glycyrrhetinate and Madecassoside in order to double the effects of anti- The present invention relates to a cosmetic composition which provides anti-inflammation and skin regenerating efficacy by mixing at least one kind thereof.

Inflammation is one of the defense mechanisms that try to minimize or minimize the reaction when cells or tissues are damaged by causes such as stress or ultraviolet rays, causing cellular reactions with nerves, blood vessels, tissues, blood, etc. As a result, they may cause itching, fever, fever, pain, and tissue damage. Under appropriate conditions, normal function is restored after the initial state of inflammation. However, when stimulants stimulating the inflammation are not removed or are continuously produced, or when inflammation is induced by various chemical mediators or cytokines secreted by cells damaged by external stimuli, As enlargement occurs and permeability increases, antibodies, plasma and phagocyte cells are packed into inflammation sites, which causes skin inflammation and skin troubles.

Causes of inflammation include external factors such as external factors, immunological factors due to antigenic responses, immunological factors caused by cellular immune responses, physical factors due to climate, environment, and chemical factors. In addition, blood vessels and hormone imbalance .

Vaso-active amines, Baso-active polypeptides, and other mediators are the mediators responsible for inflammation. Examples of vasoactive amines include histamine and serotonin secreted from mast cells And it mainly acts to enhance vasodilation and permeability. In addition, the vasoactive polypeptides include kinin, plasmin, and complement, which act as vasoconstrictors. In addition, the vasoactive polypeptides include lymphokines such as interleukin-6 (IL-6) Acid (arachidonic acid) is responsible for the inflammatory reaction. The arachidonic acid produced by the phospholipase activated by the physical and chemical stimuli is then passed through the two pathways of cyclooxygenase (COX) or lipooxygenase to produce inflammatory mediators such as prostaglandin, leukotrienes and mediate various inflammatory responses (Thomas, R., Rev. Physiol. Biochem. Pharmacol., 100, 1984, published patent 10-2008-0020853).

In human keratinocytes and Langerhans cells, various cytokines can be produced by external substances and released. These cytokines are essential for inducing skin irritation and for progression of local inflammatory reactions (J Appl Toxicol 16: 65-70, 1996). Indeed, it increases interleukin-6 (IL-6), interleukin-1 (IL-1) and Tumor necrosis factor-α (TNF-α) in stimulating contact dermatitis Contact Dermatitis 35: 355-60, 1996, Dec). In addition, there is a report that IL-6 and IL-6 (IL-6) are specifically increased by allergen-inducing substances and IL-6 and TNF-α are induced by applying specific chemicals (Am J Contact Dermat 8: 8: 158-64, 1997). The relationship of interleukin-8 (IL-8) to allergic reactions has also been reported (Contact Dermatitis, 35: 355-60, 1996 Dec). IL-1 and TNF-α are the cytokines involved in the stimulation, and IL-6 and IL-8 are allergen-related cytokines.

TNF-α is a typical cytokine secreted mainly by inflammatory cells or immune cells against external stimuli or infectious agents. It is associated with interleukin-1 (IL-1), inflammation, autoimmunity, allergy Is a proinflammatory cytokine that plays a central role in the mediation of sexually transmitted diseases. Chronic inflammatory diseases in the skin mediated by TNF-a include psoriasis, eczema or seborrheic dermatitis, and acute inflammatory diseases include contact dermatitis (Mache E and Descapms V, Ann. Dermatol. 1374-9, 2002). In addition, TNF-alpha-mediated allergic diseases include atopic dermatitis.

In order to inhibit TNF-a activity, a method of blocking TNF-α production, processing and secretion, or neutralizing TNF-α itself has been used. (TNF-α converting enzyme, TNF-α, TNF-α, TNF-α, TNF-α, (NIK, IKK, PKB) associated with the activity of NF-kB, a key signaling pathway leading to the expression of phosphodiesterase 4 and adenosine receptors, TNF-α, p38 and mitogen activated protein kinase (MAPK) such as c-jun N-terminal kinase (JNK) have been studied as a major target for inhibition of TNF-α (Patent Publication 10-2008-0051831).

Regulation of these cytokines and inhibition of the expression of inflammatory mediators can regulate stimulation and inflammation to normalize the skin. Removal of inflammation to eliminate inflammation, the action of reducing vital signs and symptoms is called anti-inflammatory. To date, substances used for antiinflammatory purposes are nonsteroidal system such as flufenamicacid, ibuprofen, benzydamine, indomethacin, and steroids such as prednisolone ), Dexamethasone, etc. In addition, neuropeptide antagonists, bradykinin antagonists, and COX inhibitors have been proposed. However, most of them have problems in terms of safety to skin and stability in cosmetic preparation, (Patent Publication No. 10-2008-0020853).

In order to solve the above problems, the inventors of the present invention have studied a combination of anti-inflammatory substances which can solve the problem of stability in the combination of anti-inflammatory effect, skin safety and cosmetic composition, and prescriptions for doubling its efficacy. As a result, And that the addition of stearyl glycyrrhetinate or didecoside doubles the anti-inflammatory effect and the effect of the skin regeneration component, thus completing the present invention.

Accordingly, it is an object of the present invention to provide a cosmetic composition that does not cause skin side effects, effectively inhibits skin inflammation, and has a skin cell regeneration effect.

In order to accomplish the above object, the present invention relates to an extract of Boswellia serrata resin; And stearyl glycyrrhetinate. The present invention also provides a cosmetic composition for improving skin sensitivity.

The cosmetic composition having the anti-inflammatory and skin regenerating effect containing the Indian oriental resin extract provided by the present invention protects the skin from external stimuli and is safe not only for primary irritation to the skin but also for the skin irritation signaling substance or inflammatory mediator Can be used for cosmetics for normalizing inflammatory skin by regulating cytokines such as TNF-a and IL-6, 8, etc., and for cosmetics for sensitive skin.

1 is a photograph showing the skin regeneration effect on cells treated with Formulation Examples 1 to 3 and Comparative Formulation Example 1 on human keratinocytes and normal cells not treated with a cosmetic composition.
FIG. 2 shows the results of analysis of IL-6 gene expression in human keratinocytes when Formulation Examples 1 to 3 and Comparative Formulation Examples 1 and 2 were treated.
FIG. 3 shows the results of analysis of IL-8 gene expression in human keratinocytes when Formulation Examples 1 to 3 and Comparative Formulation Examples 1 and 2 were treated.

The present invention relates to a cosmetic composition which further contains at least one of Stearyl glycyrrhetinate and Madecassoside as an active ingredient in Boswellia serrata resin extract, Thereby providing a cosmetic composition.

The Indian oriental resin extract used in the present invention is a resin extract obtained from Indian oriental wood. Boswellia serrata is a boswellia tree, such as Oriental wood, which is a large, largely deciduous tree that grows on dry hilly areas of India. The resin obtained from wood is similar to frankincense but with a softer flavor. The resin has long been an important ingredient in making incense, medicine, cosmetics and perfumes. The resin exudate of this plant is an external antiinflammatory agent that heals a variety of inflammatory symptoms in India and has been used in civilian usage of indigenous people. In the oriental medicine, it is said that the flavor is spicy and the taste is spicy and the mildness is mild, and it has the effect of relieving the pain and eliminating the boil, prescribing it for abdominal pain, postpartum abdominal pain, dysmenorrhea, bruise, muscle spasm and malignant tumor. Resin is used as a stimulant and rheumatism treatment. Oil obtained from resin is used as analgesic and diuretic. In the modern pharmacology field, the main uses of Indian oriental medicine are antiarthritis and anti - inflammatory. Distillation of the resin gives about 3-10% volatile essential oil, which contains anisaldehyde, alpha-pinene, alpha-phellan-drene, etc. . Inhaling the incense helps to relieve asthma, cold, and cough, and helps with colds, rheumatism, respiratory diseases and nasal congestion. Alpha, beta-boswellic acids (alpha, beta-boswellic acids) are known to act as anti-inflammatory agents. Bosswell's acid is a pro-inflammatory enzyme that induces inflammatory leukotrienes (5-lipoxygenase), a human leukocyte elastase (serine protease) that initiates tissue damage and amplifies inflammatory symptoms, (Human Leukocyte Elastase, HLE). It is also known to inhibit TNF-α, COX-2 and the like, which are typical cytokines of inflammation induction.

The extract of oriental oriental resin is prepared by drying resin of oriental oriental tree, washing with ultrapure water, extracting active ingredient with extraction solvent, and filtering, and extracting solvent is 1,3-butylene glycol, propylene glycol, ethanol, ethyl Acetate, diethyl ether, and dimethylsulfoxide. It is also possible to use a supercritical extraction method or the like.

The Indian oriental resin extract is contained in an amount of 0.01 to 10% by weight based on the total weight of the composition. In order to obtain the desired effect, the above-mentioned Indian oriental resin extract is contained in an amount of 0.01 to 10% by weight based on the total weight of the composition. When it is used in an amount of less than 0.01% by weight, it is difficult to expect an appropriate effect. When it is used in an amount exceeding 10% by weight, the safety and stability of the product may be adversely affected.

The stearyl glycyrrhizin acid used in the present invention is a glycyrrhizino acid derivative which is prepared for enhancing skin absorption and improving the stability. It is a glycyrrhizic acid derivative and has an antitumor effect, anti-ulcer, anti-inflammatory, antiallergic, anti- It is an excellent component for alleviating skin irritation and anti-inflammatory effect than chili.

Madecasoside is one of the four major components of plant extract called Centella asiatica, which grows extensively in the sub-tropics of the Indian Ocean. This plant extract has been used since ancient times for its aboriginal skin diseases and leprosy, In particular, it has been used as a medicinal medicine to treat inflammation, hyperlipidemia, inhibition of permeation of external environmental pollutants, and also promotes collagen production, It is known to keep scars as far away as possible.

Madecassoside and stearyl glycyrrhetinate are contained in an amount of 0.001 to 10% by weight based on the total weight of the composition. If the content of each component is less than 0.001 wt%, it is difficult to expect an appropriate efficacy. If the content exceeds 10 wt%, the safety and stability of the product may be adversely affected.

The cosmetic composition of the present invention prevents or alleviates skin irritation and inflammation, and provides the effect of relieving or normalizing sensitive skin.

The cosmetic composition according to the present invention is not particularly limited to the formulations and may be applied to various cosmetic compositions such as softening lotion, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing lotion, cleansing foam, It may be formulated as a pack, powder, body lotion, body cream, body oil, body essence, body cleanser, hair dye, hair tonic, scalp treatment, lotion, ointment, gel, cream, patch or spray.

Hereinafter, the composition and effect of the present invention will be described in more detail with reference to examples and test examples, but the present invention is not limited to these examples.

[Referential Example 1] Preparation of Indian oriental resin extract

First, the raw material was washed with ultrapure water, dried and pulverized. Then, the active ingredient was extracted with 200 kg of 50% 1,3-butylene glycol per 100 kg of the raw material, and filtered using a centrifuge at 250 mesh. After filtration once again with 0.5 μm filter paper, the mixture was stirred with active carbon for 2 hours for decolorization and deodorization, and then filtered sequentially from 3 μm → 1 μm → 0.5 μm → 0.3 μm → 0.2 μm to remove active carbon Completely removed. Finally, 140 kg of final product was obtained from 100 kg of resin.

[Reference Example 2] Preparation of Formulation Examples 1 to 3 and Comparative Formulation Examples 1 to 2

The cream formulations in the form of milky lotions containing the Indian frankincense extract obtained by the above method were prepared as shown in Table 1 below.

Compounding ingredient Content (% by weight) Formulation Example 1 Formulation Example 2 Formulation Example 3 Comparative Formulation Example 1 Comparative Formulation Example 2 Indian frankincense extract 1.00 1.00 1.00 1.00 - Madecasso Side 0.02 0.02 - - - Stearyl glycyrrhetinate 0.30 - 0.30 - - EDTA-2Na 0.02 0.02 0.02 0.02 0.02 glycerin 4.00 4.00 4.00 4.00 4.00 Butylene glycol 6.00 6.00 6.00 6.00 6.00 Pentaerythrityl tetraethyl hexanoate 3.00 3.00 3.00 3.00 3.00 Methofom seed oil 2.00 2.00 2.00 2.00 2.00 Squalane 2.00 2.00 2.00 2.00 2.00 Cetearyl alcohol 2.00 2.00 2.00 2.00 2.00 Behenyl alcohol 5.00 5.00 5.00 5.00 5.00 Phage-60 glyceryl isostearate 2.00 2.00 2.00 2.00 2.00 Chin type glyceryl stearate
Glucoside 1.00 1.00 1.00 1.00 1.00 Glyceryl stearate / phage-100 stearate 1.00 1.00 1.00 1.00 1.00 Hydrogenated Olive Oil Lauryl Ester 1.50 1.50 1.50 1.50 1.50 Sheer butter 2.50 2.50 2.50 2.50 2.50 Polyacrylate-13 / Polyisobutene / Polysorbate 20 0.30 0.30 0.30 0.30 0.30 Dimethicone 3.00 3.00 3.00 3.00 3.00 Preservative, fragrance, pigment Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Purified water Balance Balance Balance Balance Balance

[Test Example 1] Recovery and regeneration of skin cells: Cultivation of human keratinocytes

Human epidermal neonatal keratinocyte cells were cultured in order to examine the recovery and regeneration effect at the cell level. Human keratinocytes were purchased from Lonza, Inc. (Walkersville, MD, USA), subcultured and cultured in a CO ₂ incubator (CO ₂ In the incubator), 37 ℃, 5% CO 2 Cells were cultured under conditions. The cell culture was followed by the guidelines of Lonza, Inc. (Walkersville, MD, USA). The cells were suspended in 500 ml of KBM-2 (Clonetics CC-3103) medium using a KGM-2 bullet kit (bovine pituitary extract (BPE), human epidermal growth factor (hEGF) (Gentamycin Suflate + Amphofericin-B: GA-1) was added to the culture supernatant, and the concentration of insulin (0.5 ml), hydrocortisone (0.5 ml), transferrin (0.5 ml), epinephrine (0.5 ml) 1000, 0.5 ml)) was added thereto.

Human keratinocytes were cultured, and then Formulation Examples 1 to 3 and Comparative Formulation Example 1 were added to human keratinocyte culture medium, respectively, and cells were cultured for 24 hours to prepare samples. On the other hand, as a control group, human keratinocytes not treated with a cosmetic composition were prepared. The cells of each sample were observed under an optical microscope, which is shown in Fig.

FIG. 1 shows that cells treated with Formulation Examples 1 to 3, which are compositions containing an Indian oriental resin extract, and Comparative Example 1 were recovered. In addition, in the case of Formulation Examples 1 to 3, which further contain stearyl glycyrrhetinate or madecassoside in addition to the Indian oriental resin extract, cell recovery is more effectively performed, and both of stearyl glycyrrhetinate and methacose It can be seen that Formulation Example 1 has the best cell recovery and is most effective for cell regeneration.

[Test Example 2] Inhibitory effect of IL-6 and IL-8 on expression: Quantitative-polymerase chain reaction (Q-PCR)

Human keratinocyte cultures were treated with interferon gamma after the cultivation of human keratinocytes in the same manner as in Test Example 1, and then Formulation Examples 1 to 3 and Comparative Formulation Examples 1 and 2 were added, respectively. Cells were cultured for 24 hours, Were prepared. As a negative control group, normal cell groups without interferon gamma treatment were prepared, and human keratinocytes without a cosmetic composition treatment were prepared as a positive control group.

Twenty four hours after the material treatment, cells were washed twice with 10 ml of phosphate buffered saline (PBS) and total RNA (total RNA) was extracted from the cells using a triazole (Trizol reagent, Invitrogen, Carlsbad, CA, USA) . The isolated RNA was further purified using a Qiagen RNA kit (Qiagen, Valencia, Calif.). CDNA was synthesized from the separated RNAs using a reverse transcription kit (Superscript Reverse Transcriptase (RT) II kit, Invitrogen, Carlsbad, Calif.) And amplified by real time reverse transcription The expression of IL-6 and IL-8 was quantitatively analyzed by polymerase chain reaction (Q-RT-PCR). The expression patterns of IL-6 (Hs00174131-m1) and IL-8 (Hs00174103_m1), which are inflammatory inducers, were evaluated using TaqMan® gene expression system (TaqMan® gene expression system, Applied Biosystems, Foster City, CA) 6 gene expression analysis results are shown in Fig. 2, and the results of IL-8 gene expression analysis are shown in Fig.

As can be seen in FIGS. 2 and 3, it can be seen that IL-6 and IL-8 gene expression is decreased when Comparative Formulation Example 1 and Formulations 1 to 3 containing Indian oriental resin extract are treated . In addition, treatment with Formulations 1 to 3 containing stearyl glycyrrhetinate or madeca soside in addition to the Indian oriental resin extract resulted in more effective IL-6 and IL-8 gene expression than the Comparative Formulation Example In particular, in the case of treatment with the formulation 1, it can be confirmed that the suppression of IL-6 and IL-8 gene expression is the most excellent.

[Test Example 3] Evaluation of TNF-alpha biosynthesis inhibitory effect by stimulation with retinoic acid in dermal fibroblast

The skin fibroblasts isolated from human epidermal tissue were cultured in a 96-well test plate with DMEM (Dulbecco's Modified Eagle's Medium, BioWhitakker) containing 10% FBS (Fetal Bovine Serum, fetal bovine serum) ^Four wells were attached to each well and cultured for 24 hours. The cells were cultured for 24 hours in DMEM without FBS, and then DMEM containing 1% FBS was mixed with the Indian oriental resin extract prepared in Reference Example 1, stearyl glycyrrhetinate, and didecanoic acid as shown in the following Table 2 And then cultured for 1 hour. Then, the culture broth was taken, and an ELISA (using Pharmingen, OptEIA Human TNF-α set) for TNF-α was performed on 50 μl of each culture, Were evaluated for their ability to inhibit biosynthesis. As a negative control group, dermal fibroblasts without the test substance were used. The results are shown in Table 2 below.

ingredient Extract concentration (% by weight) TNF-a (pg / ml) % Inhibition rate * Negative control group - 1.13 - Retinoic acid (100 [mu] M) - 8.65 - Retinoic acid (100 μM) + Indian oriental resin extract Indian oriental resin extract (1.0%) 4.69 52.7 Retinoic acid (100 μM) + Indian oriental resin extract + Stearyl glycyrrhetinate + Madecassoside Indian oriental resin extract (1.32%), stearyl glycyrrhetinate (0.3%), and madecassoside (0.02%). 3.01 75.0

* Calculated based on differences in TNF-α production from cells treated with retinoic acid-treated skin fibroblasts and retinoic acid.

From the above Table 2, it can be seen that the amount of TNF-α produced by treatment with retinoic acid, which is a stimulating substance, can be suppressed by treating the composition containing the Indian oriental resin extract, and in particular, the Indian oriental resin extract, the stearyl glycyrrhetinate, It was confirmed that the biosynthesis of TNF-a, an inflammatory mediator caused by stimulation with retinoic acid, was significantly inhibited in the skin fibroblasts.

Claims (5)

delete delete delete delete A cosmetic composition for anti-inflammation and skin regeneration comprising Boswellia serrata resin extract, Stearyl glycyrrhetinate and Madecassoside.

Images